Ciphergen to Speak at American Association for Clinical Chemistry Conference
October 12 2006 - 2:01PM
PR Newswire (US)
Ciphergen Will Host AACC Proteomic Industry Workshop FREMONT,
Calif. and BALTIMORE, Oct. 12 /PRNewswire-FirstCall/ -- Ciphergen
Biosystems, Inc. (NASDAQ:CIPH) announces that Carol Berry, Head of
Corporate Marketing/North American Sales, will participate in a
panel discussion during the American Association for Clinical
Chemistry's (AACC) conference entitled "Proteomics: Opportunities
for Diagnostics, Pharmaceuticals, and the Clinical Laboratory." The
conference will focus on the future of diagnostic medicine,
biomarker discovery and the role of proteomics. Ms. Berry will
participate on the panel entitled "Cancer Diagnostic Technologies:
From Bench to the Bedside" on Saturday, October 14, 2006. Ciphergen
also is hosting an industry workshop entitled "Delivering
Proteomics to the Clinic" on Thursday, October 12, 2006 from 3:00
p.m.- 5:00 p.m. before the start of the conference. Leading experts
in proteomics and diagnostic development will present information
on the latest advancements in assay development, biomarker
validation, technology enhancements and issues surrounding the
clinical laboratory industry regulatory environment. The Saturday
commercial program will feature executives from biotech and
diagnostic companies discussing the barriers, greatest areas of
opportunity and potential contributions of proteomics to clinical
diagnostics. "Ciphergen has extensive experience in all aspects of
diagnostic development, from biomarker discovery and validation to
clinical trial design and commercialization," said Gail S. Page,
President and CEO of Ciphergen Biosystems. "The AACC panel and
industry workshop provides Ciphergen with the opportunity to
showcase its expertise bringing proteomic-based diagnostic tests to
the marketplace." The AACC conference takes place October 13-14,
2006 at the Hyatt Regency in Baltimore, MD. About Ciphergen
Ciphergen Biosystems, Inc. is dedicated to the discovery,
development and commercialization of novel high-value diagnostic
tests that help physicians diagnose, treat and improve outcomes for
patients. Ciphergen, along with its prestigious scientific
collaborators, has ongoing diagnostic programs in oncology,
cardiology and women's health with an initial focus in ovarian
cancer. Based in Fremont, California, more information about
Ciphergen can be found on the Web at http://www.ciphergen.com/ .
Ciphergen has an advanced diagnostic program in ovarian cancer and
has developed a panel of biomarkers that provides risk
stratification information for ovarian cancer based on a series of
studies involving over 2,000 clinical samples from more than five
sites. Ciphergen has an alliance with Quest Diagnostics to
commercialize this marker set under the analyte specific reagent,
or ASR, regulations. Ciphergen is simultaneously undertaking a
prospective clinical trial to support submission to the FDA for
approval as an in vitro diagnostic test. NOTE: Ciphergen,
ProteinChip and Biomarker Discovery Center are registered
trademarks of Ciphergen Biosystems, Inc. DATASOURCE: Ciphergen
Biosystems, Inc. CONTACT: Sue Carruthers, Investor Relations of
Ciphergen Biosystems, Inc., +1-510-505-2233; or media, Andrea
Campbell of WeissComm Partners, +1-281-360-7239, for Ciphergen
Biosystems, Inc. Web site: http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jul 2023 to Jul 2024